33/120
1.4 / 5 stars
All 120 Win/Lose results shown below
CRMD Roast Me summary
CorMedix Inc. (CRMD). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q23/3 |
WinCRMD / S&P 15.61% / 15.20% |
WinCRMD / S&P 280.50% / 15.00% |
WinCRMD / S&P 166.23% / 50.40% |
| 2026-Q12/3 |
LoseCRMD / S&P -41.62% / -4.33% |
WinCRMD / S&P 384.60% / 11.30% |
WinCRMD / S&P 750.00% / 27.70% |
| 2025-Q41/3 |
LoseCRMD / S&P 0.00% / 2.65% |
WinCRMD / S&P 617.03% / 9.00% |
LoseCRMD / S&P CRMD unavailable / 13.40% |
| 2025-Q30/3 |
LoseCRMD / S&P -5.60% / 8.12% |
LoseCRMD / S&P CRMD unavailable / 4.61% |
LoseCRMD / S&P CRMD unavailable / 13.45% |
| 2025-Q21/3 |
WinCRMD / S&P 100.00% / 10.94% |
LoseCRMD / S&P CRMD unavailable / 4.83% |
LoseCRMD / S&P CRMD unavailable / 10.63% |
| 2025-Q10/3 |
LoseCRMD / S&P -23.95% / -4.27% |
LoseCRMD / S&P CRMD unavailable / 4.98% |
LoseCRMD / S&P CRMD unavailable / 10.57% |
| 2024-Q40/3 |
LoseCRMD / S&P 0.25% / 2.41% |
LoseCRMD / S&P CRMD unavailable / 5.25% |
LoseCRMD / S&P CRMD unavailable / 6.15% |
| 2024-Q31/3 |
WinCRMD / S&P 86.61% / 5.89% |
LoseCRMD / S&P CRMD unavailable / 5.89% |
LoseCRMD / S&P CRMD unavailable / 6.11% |
| 2024-Q20/3 |
LoseCRMD / S&P 2.12% / 4.28% |
LoseCRMD / S&P CRMD unavailable / 5.38% |
LoseCRMD / S&P CRMD unavailable / 5.12% |
| 2024-Q11/3 |
WinCRMD / S&P 12.77% / 10.56% |
LoseCRMD / S&P CRMD unavailable / 5.71% |
LoseCRMD / S&P CRMD unavailable / 5.59% |
| 2023-Q40/3 |
LoseCRMD / S&P 1.62% / 11.69% |
LoseCRMD / S&P CRMD unavailable / 6.81% |
LoseCRMD / S&P CRMD unavailable / 7.78% |
| 2023-Q30/3 |
LoseCRMD / S&P -6.80% / -3.27% |
LoseCRMD / S&P CRMD unavailable / 7.52% |
LoseCRMD / S&P CRMD unavailable / -5.03% |
| 2023-Q20/3 |
LoseCRMD / S&P -4.11% / 8.74% |
LoseCRMD / S&P CRMD unavailable / 9.50% |
LoseCRMD / S&P CRMD unavailable / -8.57% |
| 2023-Q10/3 |
LoseCRMD / S&P -1.90% / 7.50% |
LoseCRMD / S&P CRMD unavailable / 10.77% |
LoseCRMD / S&P CRMD unavailable / -15.69% |
| 2022-Q41/3 |
WinCRMD / S&P 49.12% / 7.56% |
LoseCRMD / S&P -65.74% / 11.88% |
LoseCRMD / S&P CRMD unavailable / -17.99% |
| 2022-Q30/3 |
LoseCRMD / S&P -29.60% / -4.88% |
LoseCRMD / S&P -51.59% / 13.47% |
LoseCRMD / S&P CRMD unavailable / -1.41% |
| 2022-Q20/3 |
LoseCRMD / S&P -26.64% / -16.10% |
LoseCRMD / S&P -49.68% / 13.71% |
LoseCRMD / S&P CRMD unavailable / 11.04% |
| 2022-Q11/3 |
WinCRMD / S&P 20.44% / -4.60% |
LoseCRMD / S&P -56.47% / 15.97% |
LoseCRMD / S&P CRMD unavailable / 42.23% |
| 2021-Q40/3 |
LoseCRMD / S&P -2.15% / 11.03% |
LoseCRMD / S&P -20.19% / 15.00% |
LoseCRMD / S&P CRMD unavailable / 96.40% |
| 2021-Q30/3 |
LoseCRMD / S&P -32.22% / 0.58% |
LoseCRMD / S&P -8.66% / 10.77% |
LoseCRMD / S&P CRMD unavailable / 69.42% |
| 2021-Q21/3 |
LoseCRMD / S&P -31.33% / 8.55% |
WinCRMD / S&P 40.26% / 6.58% |
LoseCRMD / S&P CRMD unavailable / 51.81% |
| 2021-Q12/3 |
WinCRMD / S&P 34.45% / 6.17% |
WinCRMD / S&P 30.89% / -1.06% |
LoseCRMD / S&P CRMD unavailable / 7.39% |
| 2020-Q41/3 |
WinCRMD / S&P 23.22% / 12.15% |
LoseCRMD / S&P -15.55% / -3.72% |
LoseCRMD / S&P CRMD unavailable / -33.42% |
| 2020-Q30/3 |
LoseCRMD / S&P -4.29% / 8.93% |
LoseCRMD / S&P -26.92% / -2.04% |
LoseCRMD / S&P CRMD unavailable / -27.10% |
| 2020-Q21/3 |
WinCRMD / S&P 75.49% / 20.54% |
LoseCRMD / S&P -70.77% / -0.46% |
LoseCRMD / S&P CRMD unavailable / -27.11% |
| 2020-Q10/3 |
LoseCRMD / S&P -50.69% / -19.60% |
LoseCRMD / S&P -66.05% / 3.47% |
LoseCRMD / S&P CRMD unavailable / -14.75% |
| 2019-Q41/3 |
WinCRMD / S&P 14.11% / 9.07% |
LoseCRMD / S&P -34.09% / 5.36% |
LoseCRMD / S&P CRMD unavailable / 2.99% |
| 2019-Q30/3 |
LoseCRMD / S&P -28.87% / 1.70% |
LoseCRMD / S&P -42.52% / 5.02% |
LoseCRMD / S&P CRMD unavailable / 0.21% |
| 2019-Q21/3 |
LoseCRMD / S&P -5.08% / 4.30% |
WinCRMD / S&P 224.36% / 6.64% |
LoseCRMD / S&P CRMD unavailable / 8.65% |
| 2019-Q12/3 |
WinCRMD / S&P 46.51% / 13.65% |
WinCRMD / S&P 82.21% / 8.12% |
LoseCRMD / S&P CRMD unavailable / 14.29% |
| 2018-Q42/3 |
WinCRMD / S&P 32.99% / -13.52% |
WinCRMD / S&P 30.51% / 9.05% |
LoseCRMD / S&P CRMD unavailable / 18.23% |
| 2018-Q32/3 |
WinCRMD / S&P 304.17% / 7.71% |
WinCRMD / S&P 38.29% / 10.21% |
LoseCRMD / S&P CRMD unavailable / 19.06% |
| 2018-Q21/3 |
WinCRMD / S&P 33.33% / 3.43% |
LoseCRMD / S&P -46.08% / 9.03% |
LoseCRMD / S&P CRMD unavailable / 14.46% |
| 2018-Q11/3 |
LoseCRMD / S&P -64.00% / -0.76% |
WinCRMD / S&P 40.83% / 7.68% |
LoseCRMD / S&P CRMD unavailable / 12.46% |
| 2017-Q41/3 |
LoseCRMD / S&P -3.85% / 6.64% |
WinCRMD / S&P 46.95% / 7.03% |
LoseCRMD / S&P CRMD unavailable / 13.82% |
| 2017-Q32/3 |
WinCRMD / S&P 20.93% / 4.48% |
WinCRMD / S&P 186.05% / 5.68% |
LoseCRMD / S&P CRMD unavailable / 17.57% |
| 2017-Q21/3 |
LoseCRMD / S&P -73.62% / 3.09% |
WinCRMD / S&P 192.64% / 4.83% |
LoseCRMD / S&P CRMD unavailable / 17.74% |
| 2017-Q11/3 |
WinCRMD / S&P 6.54% / 6.07% |
LoseCRMD / S&P 0.88% / 3.67% |
LoseCRMD / S&P CRMD unavailable / 13.32% |
| 2016-Q41/3 |
LoseCRMD / S&P -39.29% / 3.82% |
WinCRMD / S&P 6.65% / 2.09% |
LoseCRMD / S&P CRMD unavailable / 7.05% |
| 2016-Q31/3 |
WinCRMD / S&P 26.63% / 3.85% |
LoseCRMD / S&P -53.94% / 0.20% |
LoseCRMD / S&P CRMD unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | CRMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -43.96% | 20.78% |
| Annualized return | -43.96% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | CRMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 29.24% | 83.14% |
| Annualized return | 5.26% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | CRMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -12.98% | 319.30% |
| Annualized return | -1.38% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |